<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-312
Date of Submission: 2025-07-01

This report was submitted by a Physician from Murphy-Hernandez Medical Center concerning patient ANON-PX-1741. The subject is a 36-year-old other with a significant medical history including type 2 diabetes, osteoarthritis, migraines, chronic kidney disease. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Warfarin administered via the Subcutaneous route at a dosage of 194mg, initiated on 2025-06-17 for Thromboembolism prevention and discontinued on 2025-06-28; Gabapentin administered via the Subcutaneous route at a dosage of 125mg, initiated on 2025-06-17 for Neuropathic pain and discontinued on 2025-06-28.

On approximately 2025-06-27, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Maculopapular Rash, Stevens-Johnson syndrome. The Maculopapular Rash was classified as Mild in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Unknown'. The Stevens-Johnson syndrome was classified as Mild in severity. This necessitated clinical intervention. The documented action was: Prescribed beautiful and advised moment. The current patient status regarding this symptom is 'Recovering'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 2 was calculated, The assessment concluded the relationship was 'Possible'. Dechallenge/Rechallenge status was noted as: 'Positive rechallenge'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Important base yet star oil bad involve blood. Reality see college not military age try.</data>
report_id: ADR-2025-312
report_date: '2025-07-01'
patient_details:
  patient_id: ANON-PX-1741
  gender: Other
  relevant_history:
  - type 2 diabetes
  - osteoarthritis
  - migraines
  - chronic kidney disease
  age_at_reaction: 36
suspected_drugs:
- drug_name: Warfarin
  dosage: 194mg
  route_of_administration: Subcutaneous
  start_date: '2025-06-17'
  indication_for_use: Thromboembolism prevention
  end_date: '2025-06-28'
- drug_name: Gabapentin
  dosage: 125mg
  route_of_administration: Subcutaneous
  start_date: '2025-06-17'
  indication_for_use: Neuropathic pain
  end_date: '2025-06-28'
adverse_reactions:
- symptom_name: Maculopapular Rash
  onset_date: '2025-06-27'
  severity: Mild
  outcome: Unknown
  intervention_required: false
- symptom_name: Stevens-Johnson syndrome
  onset_date: '2025-06-27'
  severity: Mild
  outcome: Recovering
  intervention_required: true
  intervention_details: Prescribed beautiful and advised moment.
causality_assessment:
  assessment_conclusion: Possible
  dechallenge_rechallenge: Positive rechallenge
  naranjo_score: 2
reporting_facility: Murphy-Hernandez Medical Center
reporter_type: Physician
notes: Important base yet star oil bad involve blood. Reality see college not military
  age try.
